Neurocrine Biosciences Inc (NBIX)
Financial leverage ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | US$ in thousands | 3,718,700 | 3,535,000 | 3,305,000 | 3,472,400 | 3,251,400 | 2,848,200 | 2,613,100 | 2,359,800 | 2,368,700 | 2,143,400 | 2,005,700 | 2,144,500 | 2,072,500 | 2,017,300 | 1,956,400 | 1,846,400 | 1,734,700 | 1,502,600 | 1,515,600 | 1,361,900 |
| Total stockholders’ equity | US$ in thousands | 2,589,700 | 2,718,900 | 2,509,200 | 2,386,100 | 2,232,000 | 2,002,100 | 1,853,000 | 1,684,500 | 1,707,800 | 1,544,600 | 1,423,400 | 1,391,100 | 1,374,000 | 1,346,000 | 1,279,200 | 1,205,600 | 1,126,200 | 804,300 | 831,200 | 700,300 |
| Financial leverage ratio | 1.44 | 1.30 | 1.32 | 1.46 | 1.46 | 1.42 | 1.41 | 1.40 | 1.39 | 1.39 | 1.41 | 1.54 | 1.51 | 1.50 | 1.53 | 1.53 | 1.54 | 1.87 | 1.82 | 1.94 |
December 31, 2024 calculation
Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $3,718,700K ÷ $2,589,700K
= 1.44
The financial leverage ratio of Neurocrine Biosciences Inc has shown a fluctuating trend over the past five years, ranging from a high of 1.94 in March 2020 to a low of 1.30 in September 2024. This ratio indicates the company's level of debt financing relative to its equity. A higher leverage ratio suggests higher financial risk due to increased dependence on debt, while a lower ratio indicates a lower level of debt relative to equity.
Neurocrine Biosciences Inc experienced a downward trend in its financial leverage ratio from 2020 to 2022, reaching its lowest point of 1.39 in September 2022. However, the ratio started to increase slightly in 2023 and continued to rise in 2024, reaching 1.44 by December 2024. This could imply that the company may have increased its debt levels relative to equity during this period.
It is important for investors and stakeholders to closely monitor the financial leverage ratio of Neurocrine Biosciences Inc to assess the company's ability to handle its debt obligations and manage financial risk effectively.
Peer comparison
Dec 31, 2024